Literature DB >> 22826755

Hepatitis C among Intravenous Drug Users in Isfahan, Iran: a Study of Seroprevalence and Risk Factors.

Zary Nokhodian1, Marjan Meshkati, Peyman Adibi, Behrooz Ataei, Nazila Kassaian, Majid Yaran, Parisa Shoaei, Razieh Hassannejad.   

Abstract

OBJECTIVES: Hepatitis C virus (HCV) is one of the major public health problems worldwide which is transmitted through contact with infected blood or blood products. One of the most prevalent modes of HCV transmission is injecting drug with unclean needles or syringes. Therefore intravenous drug users (IVDUs) are the most important group who should be considered. The aim of this study was to evaluate seroprevalence and risk factors of hepatitis C virus in IVDUs population.
METHODS: The cross-sectional study was carried out on intravenous drug users who attended health and social care Drop-in centers during November 2008 to February 2009 in Isfahan province, Iran. Data was gathered using interviewer-administered questionnaire including demographic characteristics and main risk factors for HCV infection. 5ml venous blood sample was obtained from each subject. The HCV-Ab test was performed on all blood samples by ELISA. The data was analyzed using descriptive statistical methods and multiple logistic regressions by SPSS software, version 15.
RESULTS: The mean age of participants was 31.77 ± 8.51. 503 (94.7%) were men and 28 (5.3%) were women. HCV seroprevalence was 47.1% (95% CI: 42.9, 51.3). The multiple logistic regressions demonstrated that history of tattooing (OR 1.72, 95% CI 1.02-2.90), history of imprisonment (OR 2.49, 95% CI 1.40-4.42) and sharing needles/syringes (OR 2.76, 95% CI 1.54-4.95) are significant predictors of risk of HCV in IVDU population.
CONCLUSIONS: In conclusion, according to the high prevalence of HCV infection among IVDUs and high adds of HCV infection from tattooing, sharing of needles/syringes and imprisonment, effective harm reduction programs should be expanded among IVDUs to prevent new HCV infections.

Entities:  

Keywords:  Hepatitis C virus; High-risky behaviors; Intravenous drug users; Risk factors

Year:  2012        PMID: 22826755      PMCID: PMC3399288     

Source DB:  PubMed          Journal:  Int J Prev Med        ISSN: 2008-7802


INTRODUCTION

Hepatitis C virus (HCV) is one of the major public health problems worldwide which is transmitted through contact with infected blood or blood products. HCV infection causes critical medical consequence such as cirrhosis and liver diseases.[1] Among individuals with HCV infection, 85% will acquire chronic HCV infection.[2] WHO has reported a prevalence of 3% for HCV in the world and more than 170 million persons have been infected with this virus globally.[3] Countries in Africa, Asia and Southern Europe have demonstrated high prevalence of HCV infection.[4] There is no overall estimate of hepatitis C infection in Iran. A systematic review study on HCV which assessed general population in Iran, has estimated prevalence of 0.16% for HCV infection. The prevalence ranged from 0% in Khuzestan and Tahren province to 1.3% in Guilan province.[5] HCV infection can be transmitted through many routes. Due to the most prevalent mode of HCV transmission is injecting drug with unclean needles or syringes, intravenous drug users (IVDUs) are the most important group who should be considered.[1] It has been estimated 2-4 million people in developing countries possess HCV infection driven by unsafe injection drug use each year that is extending to other population.[4] There is wide range of prevalence estimates around the world. Considering a systematic review study's results, prevalence of HCV infection among IVDUs ranged from 1.9% to 100%.[6] Identification of HCV infection epidemiology is important to perform proper harm reduction program to control and prevent infection transmission and chronic liver diseases.[4] Therefore the seroprevalence and main way of HCV transmission in developing countries should be accessible.[7] There aren’t enough appropriate epidemiological studies of HCV in developing countries. A number of studies have evaluated HCV prevalence in IVDUs population in Iran. More recent studies among IVDUs have indicated HCV prevalence of 11.2-88.9%.[28-18] Those observations raised concern about IVDUs and high risky behaviors among them and as a result transmission and spread of HCV.[19] Therefore it is considerable to prevent HCV and decrease its dire consequences like liver diseases by decrease of infection among IVDUs and assessing other high-risky behaviors among them to control extension of infection from them to other groups and public population eventually.[4] According to lack of information on HCV prevalence among IVDUs in Isfahan province, Iran, this study evaluated the prevalence and risk factors for HCV infection among IVDUs referred drop in centers (DICs) in that province. DICs are one of the important centers where present services to social vulnerable individuals. They conduct harm reduction programs with aim to prevent transmission of infection diseases and reduce spread of them in public community. The harm reduction programs include exchanging needles or syringes, distribution of condoms and providing methadone maintenance treatment among IVDUs who refer there. Therefore DICs are one of the places of IVDUs aggregation. The main aim of this study is to provide worth information about prevalence and risk factors of hepatitis C in IVDUs population and it will be helpful for prevention and therapeutic interventions.

METHODS

The cross-sectional study was carried out on intravenous drug users who attended health and social care Drop-in centers during November 2008 to February 2009 in Isfahan province, Iran. Required information was gathered using interviewer-administered questionnaire including demographic characteristics and main risk factors for HCV infection. For each participant an educated interviewer, who was social worker and had been working with our target population and was trusty for them, filled out questionnaires with face-to-face interview. All IVDUs who referred to DICs were requested to take part in the study after being informed about the goal and process of the study and promised all data were kept private. According to ethical issues the individual took part in the study voluntary and they were not encouraged for participation. After that they filled out a consent form. Also the subjects were allowed to leave out any question which they weren’t satisfied about answering to it. This study was approved by the ethical committee of Isfahan University of Medical Sciences. Face and content validity of questionnaire was confirmed by eight experts. Cronbach Alpha indicated reasonable reliability (r = 0.78). After completion of questionnaire, 5 ml venous blood sample was obtained from each subject. Serum samples were transferred to the Isfahan infectious diseases research center laboratory and stored at –20 °C. The HCV-Ab test was performed on all blood samples by Italian Diasorin enzymelinked immunosorbant assay (ELISA) kits. The collected data was analyzed by SPSS software, version 15. Prevalence of hepatitis C virus was estimated using descriptive statistical methods. Bivariate associations between risk factors and HCV were assessed by Chi-square test. Multiple logistic regressions were applied to calculate adjusted odds Ratio for risk factors related to HCV. A probability of <0.05 was considered as statistical significant. All variables that were found to be significant in the bivariate analysis were taken into logistic regression. According to the multicollinearity is a statistical phenomenon in which two or more predictor variables in a multiple regression model are highly correlated and it affects parameter estimations. We include one of variables in those groups that had association with each other into regression model after consultation with clinicians. For example among history of imprisonment, duration of being in prison and number of imprisonment, we only involved history of imprisonment into regression model to avoid collinearity.

RESULTS

Of 539 intravenous drug users who participated in this study, the sample blood of 531 individuals could be tested for HCV positivity. Therefore 531 subjects were analyzed according to the obtained information. We found HCV seroprevalence was 47.1% (95% CI: 42.9, 51.3) among IVDUs. The mean age of participants was 31.77 ± 8.51. 503 (94.7%) were men and 28 (5.3%) were women. 274 (55.9%) of subjects were employed and 278 (52.4%) were single. Regarding education, most of the participants (66.3%) had low level of education (under Diploma). Table 1 describes the distribution of HCV prevalence within each demographic characteristics and their bivariate association. As seen in this table age, employment status and education had significant association with HCV seropositivity.
Table 1

Bivariate association between demographic characteristics and HCV seropositivity

Bivariate association between demographic characteristics and HCV seropositivity Some potential risk factors for HCV were shown in table 2. Sharing needles/syringes and history of illegal sex had been reported by 130 (33.1%) and 294 (55.5%) subjects respectively. Among male participants who had history of illegal sexual activity, 228 (79.7%) had heterosexual contact, 95 (33.2%) had experience of homosexual contact, 136 (48.4%) had reported using condom in their contact and 127 (44.3%) had practiced sexual contact with female sex workers. Of sexual active participants, 47 (18.7%) had one sexual partner, 97 (38.6%) two to nine sexual partners, 106 (42.2%) more than nine sexual partners and 70 (30%) reported sexual practice with IVDUs. There were no significant association between sexual behaviors and HCV prevalence.
Table 2

Bivariate association between potential risk factors and HCV seropositivity

Bivariate association between potential risk factors and HCV seropositivity As depicted in table 2, variety of risk factors were associated with HCV prevalence such as history of tattooing, surgery, suture, tooth filling, sharing needles/syringes, history of imprisonment, duration of being IDVU, duration of being in prison and number of imprisonment. The multiple logistic regressions demonstrated that history of tattooing, history of imprisonment and sharing needles/syringes are significant predictors of risk of HCV in IVDU population. The other variables which had been significant in bivariate analysis were not statistically significant in multiple logistic regression [Table 3].
Table 3

Multiple logistic regression of potential risk factors for HCV seropositivity

Multiple logistic regression of potential risk factors for HCV seropositivity

DISCUSSION

In this study we assessed the seroprevalence of HCV infection among intravenous drug users. Prevalence of HCV positivity was 47.1%. Different studies have estimated the seroprevalence of HCV among IVDUs. Similar studies around the world have shown wide range. In a systematic review study which was done by Aceijas et al.,[6] prevalence of HCV was evaluated among injecting drug users between 1998 and 2005. They have reported various estimates, 10-96% in Eastern Europe and central Asia, 10-100% in South and South-East Asia, 34-93% in East-Asia and the Pacific, 5-60% in North Africa and the Middle East, 2-100% in Latin America, 8-90% in North America, 25-88% in Australia and New Zealand and 2-93% in Western Europe. But in Colombia and Lebanon, HCV prevalence was less than 20%. In Studies which were conducted in the population of IVDUs in Iran, high HCV prevalence was observed (11.2% to 88.9%)[28-18]. Except for study in Shahr-e-Kord (11.2%), all of studies have reported HCV prevalence of at least 30%. According to the high seropositivity of HCV among IVDUs, they play significant epidemiological role in the transmission of HCV infection. Therefore this population is the most important group who should be considered to control and decrease the spread of HCV among them.[20] Since the high-risky behaviors in intravenous drug users frequently happen, we evaluated some risk factors associated with HCV positivity. The result of multiple logistic regression showed subjects who had history of tattooing, sharing needles/syringes and imprisonment, were more likely to be positive for HCV. Our findings displayed compare with non-needle-sharing, participants who shared needles /syringes had significant higher odds of having HCV infection. Odds of getting HCV infection among this group was 2.76 times more than non-needle–sharing participants. This finding is in agreement with some earlier studies.[3101317-192122] Thus, conducting proper harm reduction programs such as exchange needles/ syringes among IVDUs are urgently needed. Tattooing is one of the fashionable human activities these days. In our study there was significant association between history of tooting and HCV positivity. Having experience of tattooing increases odds of infection by 72%. In the United States, Samuel et al.[23] have observed doing tattoo inside prison was related with HCV prevalence (OR = 3.4). In Australia and Italy it was also significant independent risk factor for HCV positivity among a group of prisoners (OR = 2.7 and 1.91 respectively).[2425] A number of studies among IVDUs in Iran have also found significant association between being tattooed and HCV prevalence.[81118] Also Pourahmad et al.[3] have reported tattooing as significant risk factors of HCV positivity in sample of prisoners. Two other studies[1226] found this relationship among addicted prisoners. Since the tattooing is common in Iran prisons and most of the people who attend this behavior, do it in illegal places, it is probably being done using unsteril equipments. As a result, contact with infections blood can be occurred through unsafe tattooing.[3] Consistent with previous investigations,[210141822] we found that imprisonment is another significant independent factor for HCV seropositivity. Odds of being HCV positive among IVDUs with history of incarceration was 2.49 times more than odds of carrying the infection among IVDUs without history of being in prison. Prisons are substantial places where the prisoners experience high-risky behaviors there such as sharing of injection equipments, tattooing and unprotected sexual behaviors. There-fore imprisonment may accompany with risky behaviors that increase risk of infection transmission in prison and prisons should be considered as a priority site to make decision concerning harm reduction strategies among prisoners.[14] Similar to another study in Iran,[14] we found no statistical association between sexual activity and prevalence of HCV. This finding is not consistent with previous reports.[2122] It may be because of religious beliefs that affect answering to sexual activities questions. Ultimately, this study has some limitations. First, the sample is not representative of intravenous drug users as subjects took part in the study from only health and social care centers (DICs) in Isfahan province. Furthermore, our data was gained based on self-reported information through interview and participants were allowed to skip any questions which they weren’t satisfied about answering to them. Therefore, there were some unanswered questions especially about sexual behaviors. In conclusion, according to the high prevalence of HCV infection among IVDUs and high adds of HCV infection from tattooing, sharing of needles/syringes and imprisonment, effective harm reduction programs should be expanded among IVDUs to prevent new HCV infections. In addition it is important that potential affection of prison on spread of HCV infection throughout the community be taken into consideration in order to control transmission of HCV infection society.
  19 in total

1.  The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities.

Authors:  M E Hellard; J S Hocking; N Crofts
Journal:  Epidemiol Infect       Date:  2004-06       Impact factor: 2.451

2.  Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan--Iran.

Authors:  Amir Houshang Mohammad Alizadeh; Seyed Moayed Alavian; Khalil Jafari; Nastaran Yazdi
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

3.  Prevalence and risk factors for hepatitis C virus infection among young Thai men.

Authors:  Anchalee Jatapai; Kenrad E Nelson; Thippawan Chuenchitra; Khunakorn Kana; Sakol Eiumtrakul; Ekachai Sunantarod; Ram Rangsin
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

4.  History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin.

Authors:  K Stark; U Bienzle; R Vonk; I Guggenmoos-Holzmann
Journal:  Int J Epidemiol       Date:  1997-12       Impact factor: 7.196

Review 5.  Global estimates of prevalence of HCV infection among injecting drug users.

Authors:  Carmen Aceijas; Tim Rhodes
Journal:  Int J Drug Policy       Date:  2007-08-07

6.  Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Guilan province.

Authors:  Z Mohtasham Amiri; M Rezvani; R Jafari Shakib; A Jafari Shakib
Journal:  East Mediterr Health J       Date:  2007 Mar-Apr       Impact factor: 1.628

7.  High Prevalence of Hepatitis C virus Among Injection Drug Users in Zhenjiang, Jiangsu, China.

Authors:  Nana Wu; Qinjuan Ge; Qingchuan Feng; Jun Zhang; Xiaoxia Liu; Caihong Sun; Yongkang Xu; Guangli He; Chiyu Zhang
Journal:  Indian J Virol       Date:  2011-06-30

8.  HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran.

Authors:  Afarin Rahimi-Movaghar; Emran M Razaghi; Elaheh Sahimi-Izadian; Masoumeh Amin-Esmaeili
Journal:  Int J Infect Dis       Date:  2009-05-21       Impact factor: 3.623

9.  Seroprevalence of HBV, HCV and HIV infection among intravenous drug users in Shahr-e-Kord, Islamic Republic of Iran.

Authors:  R Imani; A Karimi; R Rouzbahani; A Rouzbahani
Journal:  East Mediterr Health J       Date:  2008 Sep-Oct       Impact factor: 1.628

10.  HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan.

Authors:  Catherine S Todd; Abdullah M S Abed; Steffanie A Strathdee; Paul T Scott; Boulos A Botros; Naqibullah Safi; Kenneth C Earhart
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883

View more
  17 in total

Review 1.  Epidemiology of hepatitis C virus in Iran.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

2.  Burden of blood transmitted infections in substance users admitted for inpatient treatment in Singapore and the associated factors.

Authors:  Rochelle Melina Kinson; Song Guo; Yi Min Wan; Victoria Manning; Hui Chin Teoh; Kim Eng Wong
Journal:  Singapore Med J       Date:  2015-02       Impact factor: 1.858

Review 3.  High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001-2012).

Authors:  Mohsen Malekinejad; Soodabeh Navadeh; Ali Lotfizadeh; Afarin Rahimi-Movaghar; Masoumeh Amin-Esmaeili; Alireza Noroozi
Journal:  Int J Infect Dis       Date:  2015-10-13       Impact factor: 3.623

4.  An emerging trend of methamphetamine injection in iran: a critical target for research on blood-borne infection diseases.

Authors:  Zahra Alam Mehrjerdi; Alireza Noroozi
Journal:  Hepat Mon       Date:  2013-02-28       Impact factor: 0.660

5.  Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa.

Authors:  Ghina R Mumtaz; Helen A Weiss; Peter Vickerman; Natasha Larke; Laith J Abu-Raddad
Journal:  AIDS       Date:  2015-08-24       Impact factor: 4.177

6.  The long-term effectiveness of methadone maintenance treatment in prevention of hepatitis C virus among illicit drug users: a modeling study.

Authors:  Mehdi Javanbakht; Alireza Mirahmadizadeh; Atefeh Mashayekhi
Journal:  Iran Red Crescent Med J       Date:  2014-02-07       Impact factor: 0.611

7.  Unprotected anal Intercourse among Iranian Intra-Venous Drug Users.

Authors:  Parvaneh Mirabi; Mosayeb Yarmohammadi Vasel; Babak Moazen; Mahmoud Sehat; Majid Rezazadeh; Khodabakhsh Ahmadi
Journal:  Front Public Health       Date:  2013-09-26

8.  Perceived Risk Modifies the Effect of HIV Knowledge on Sexual Risk Behaviors.

Authors:  Gholamhossein Noroozinejad; Mosaieb Yarmohmmadi Vasel; Fatemeh Bazrafkan; Mahmoud Sehat; Majid Rezazadeh; Khodabakhsh Ahmadi
Journal:  Front Public Health       Date:  2013-09-30

Review 9.  Prevalence of HIV and HCV among injecting drug users in three selected WHO-EMRO countries: a meta-analysis.

Authors:  Shah Jahan Shayan; Rajab Nazari; Frank Kiwanuka
Journal:  Harm Reduct J       Date:  2021-05-27

10.  Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users.

Authors:  Seyed Moayed Alavian; Alireza Mirahmadizadeh; Mehdi Javanbakht; Ali Keshtkaran; Alireza Heidari; Atefeh Mashayekhi; Shima Salimi; Mohammad Hadian
Journal:  Hepat Mon       Date:  2013-08-17       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.